Radiotherapy in early stage follicular lymphoma: is it really the gold standard?
| Autoři | |
|---|---|
| Rok publikování | 2015 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Leukemia and Lymphoma |
| Fakulta / Pracoviště MU | |
| Citace | |
| Doi | http://dx.doi.org/10.3109/10428194.2015.1049172 |
| Obor | Ostatní lékařské obory |
| Klíčová slova | Radiotherapy; follicular lymphoma |
| Popis | Major changes have occurred during the last few years in the management of follicular lymphoma (FL), leading to substantial improvement in prognosis and overall survival. One of the turning points was the introduction of rituximab (R). Th is monoclonal antibody is now the cornerstone of therapy for advanced disease and is now a standard part of treatment. However, for the 25 – 30% patients with localized disease (stage I or II), involved-fi eld radiotherapy (IFRT) remains the gold standard [1]. We can indeed ask if this treatment modality is truly the gold standard? |